LONDON BROKER RATINGS: Deutsche Bank Research cuts Eurowag to 'hold'
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
Price | 11,396.00p on 17-09-2025 | at 17:50:04
---|---|
Change | 50.00p 0.44% |
Buy | 11,380.00p |
Sell | 11,376.00p |
Last Trade: | Unknown 6.00 at 11,356.49783p |
Day's Volume: | 1,404,238 |
Last Close: | 11,396.00p |
Open: | 11,338.00p |
ISIN: | GB0009895292 |
Day's Range | 11,246.00p - 11,400.00p |
52wk Range: | 9,574.00p - 12,256.00p |
Market Capitalisation: | £176.67b |
VWAP: | 11,368.05164p |
Shares in Issue: | 1.55b |
Astrazeneca (AZN) Latest Trades |
||||
Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
---|---|---|---|---|
Unknown* | 6 | 11,356.49783p | Currency Conversion Negotiated Trade OTC Trade |
17:33:44 - 17-Sep-25 |
Unknown* | 129 | 11,300.14445p | Currency Conversion Negotiated Trade OTC Trade |
17:32:59 - 17-Sep-25 |
Sell* | 1,800 | 11,396.00p | Automatic Execution |
16:37:58 - 17-Sep-25 |
Sell* | 75 | 11,396.00p | Automatic Execution |
16:37:58 - 17-Sep-25 |
Sell* | 250 | 11,396.00p | Automatic Execution |
16:37:58 - 17-Sep-25 |
Sell* | 600 | 11,396.00p | Automatic Execution |
16:37:31 - 17-Sep-25 |
Sell* | 600 | 11,396.00p | Automatic Execution |
16:37:30 - 17-Sep-25 |
Sell* | 600 | 11,396.00p | Automatic Execution |
16:37:30 - 17-Sep-25 |
Sell* | 600 | 11,396.00p | Automatic Execution |
16:37:30 - 17-Sep-25 |
Sell* | 1,200 | 11,396.00p | Automatic Execution |
16:37:29 - 17-Sep-25 |
Astrazeneca (AZN) Regulatory News |
||
Date | Source | Headline |
---|---|---|
1st Sep 2025 3:00 pm | RNS | Total Voting Rights |
28th Aug 2025 3:00 pm | RNS | Holding(s) in Company |
26th Aug 2025 3:00 pm | RNS | Holding(s) in Company |
21st Aug 2025 3:00 pm | RNS | Holding(s) in Company |
18th Aug 2025 3:00 pm | RNS | Director/PDMR Shareholding |
15th Aug 2025 3:00 pm | RNS | Holding(s) in Company |
12th Aug 2025 3:00 pm | RNS | Holding(s) in Company |
1st Aug 2025 3:00 pm | RNS | Total Voting Rights |
29th Jul 2025 7:00 am | RNS | H1 and Q2 2025 results |
24th Jul 2025 7:00 am | RNS | Gefurulimab nanobody met Phase III endpoints |